louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06430710: Tooth Borne Versus Temporary Anchorage Devices (TAD) Based Intrusion Systems for the Correction of Anterior Deep Overbite
Official title: Tooth Borne Versus Temporary Anchorage Devices Based Intrusion Systems for the Correction of Anterior Deep Overbite;Oral Hygiene, Pain and Treatment Effect
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Deep Overbite
Keywords: Anterior deep bite
Intrusive arch
Miniscrews
Lead sponsor: Faculty of Dental Medicine for Girls
Sponsor class: OTHER_GOV
First posted: 2024-05-28
Enrollment: 16
Sex: ALL
Minimum age (years): 15
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Sixteen patients with anterior deep over bite participated in two groups each group contains eight patients
Primary purpose: TREATMENT

Brief summary: Compare the tooth borne versus fixed orthodontic intrusive system (TADs) for the correction of anterior deep overbite

Detailed description: this study determined which method was more compliant, efficacy and comfortable. It was performed to evaluate intrusion of upper incisors with applying tooth borne system as Connecticut Intrusion Arch (CIA) and temporary anchorage devices (TADs) \[miniscrew\] and evaluate the dental and skeletal cephalometric effects of these intrusion methods on individuals with deep bite caused by supraocclusion of upper incisors. It also evaluated oral hygiene and pain sensation in the two groups during the study period.

Eligibility criteria: Inclusion Criteria:

1. Class I or Class II malocclusion with minimal crowding.
2. 70% to 100% overbite.
3. High lip line with gingival display on smiling and super-eruption of maxillary incisors.
4. All patients had permanent dentition with average to vertical growth pattern and curve of Spee of 4mm or less.

Exclusion Criteria:

1. Having missing teeth on the anterior maxillary area.
2. Any history of trauma or root canal treatment.
3. Previous orthodontic treatment.
4. Low lip line duing social smile.
5. Having any hormonal disorder or syndromes.

Primary outcomes:
measure: Measure distance of insicors intrusion
timeFrame: 2 years
Secondary outcomes:
measure: Pain intensity
timeFrame: 8 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University
Study officials:
References:
Clinical trial NCT05913310: Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia
Official title: A Randomized Controlled Study of Kui-Yuan Chewable Tablets in the Treatment of Hyperuricemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Hyperuricemia
Keywords: Hyperuricemia
Kui-Yuan Chewable
Randomized controlled trial
Lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Sponsor class: OTHER
First posted: 2023-06-22
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a multi-center, randomized, double-blinded, controlled trial with two parallel arms. The aim of the study is to evaluate efficacy and safety of Kui-Yuan chewable tablets in patients with hyperuricemia.


Eligibility criteria: Inclusion Criteria:

* Blood uric acid level\>7.0mg/dL (420 μmol/L)
* The participants did not experience any acute gout attacks before treatment
* The ECG of the participants was normal before treatment

Exclusion Criteria:

* Secondary Hyperuricemia caused by kidney disease, blood disease, or taking certain drugs, tumor radiotherapy and chemotherapy, organ transplantation, etc
* Those who have used allopurinol, probenecid, benzbromarone, febuxostat or traditional Chinese medicine with uric acid lowering effect within 4 weeks before enrollment
* Those who had a history of cardiovascular and cerebrovascular diseases such as stroke, TIA, MI, HF (NYHA grade II-IV), and coronary artery surgery (such as angioplasty, stent implantation, bypass grafting, etc.)
* Those who had a history of gastrointestinal ulcers or gastrointestinal bleeding
* Active liver disease or abnormal liver function, ALT and AST are more than 3 times the upper limit of normal
* Glomerular filtration rate (eGFR)\<30mL/min/1.73m2
* Those who are allergic or intolerant to any component in Kui-Yuan chewable tablets and placebo
* Those who had other autoimmune diseases
* Those who are taking or need to take aspirin, other salicylic acids, heparin, Dicoumarol and other anticoagulants and antiplatelet aggregation drugs
* Those who taking Diuretic
* Those who had a history of alcohol or drug dependence, or those who require long-term daily use of painkillers for any reason
* Pregnancy, lactation, or planned pregnancy within 3 months after the last study medication

Primary outcomes:
measure: Proportion of sUA levels below 420 μmol/L
timeFrame: 3 months
Secondary outcomes:
measure: Proportion of sUA levels below 360 μmol/L
timeFrame: 3 months
measure: The number of gout attacks
timeFrame: 3 months
measure: Proportion of gout attacks
timeFrame: 3 months
measure: Percentage change in sUA levels
timeFrame: 3 months
measure: Changes in BMI
timeFrame: 3 months
measure: Changes in blood pressure levels
timeFrame: 3 months
measure: Changes in blood lipid levels
timeFrame: 3 months
measure: Changes in fasting blood glucose levels
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02746510: Validation of a Clinical Screening Grid for Syndromic Schizophrenia
Official title: Validation of a Clinical Screening Grid for Syndromic Schizophrenia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Schizophrenia
Lead sponsor: Hôpital le Vinatier
Sponsor class: OTHER
Collaborators: name: Hospices Civils de Lyon
First posted: 2016-04-21
Enrollment: 129
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Background:

Nowadays, despite a large number of studies about schizophrenia and genetics, clinical red flags for syndromic forms of schizophrenia remain poorly documented.

Detailed description: Methods: This study aims to validate a short clinical screening grid for syndromic forms of schizophrenia linked to a pathogenic Copy Variation Number (CNV). The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV).

In subjects with no CNV that may explain the onset of schizophrenia, the investigators would like to complete the investigations with exome trio sequencing. With this type of very clinical approach, the investigators wish to determine which semiological elements should alert the psychiatrists as to the presence of a syndromic form. The objective is to propose at the end of this study a simple and reliable scale, usable in psychiatry consultation, to guide the genetic screening of forms of syndromic schizophrenia.

Eligibility criteria: Inclusion Criteria:

* Patient aged 15 years and more with a schizophrenia defined by the DSM V criterion
* Informed consent signed by the patient or he/she's legal representant

Exclusion Criteria:

* Pregnancy
* Current psychotic decompensation
* Patient with a known genetic syndrome

Primary outcomes:
measure: Presence or absence of each criteria from the grid.
timeFrame: During the inclusion visit (45 minutes)
Secondary outcomes:
measure: Presence or absence of a pathogenic CNV detected on the CGH-a
timeFrame: 4 months from samples to results
measure: Whole exome sequencing
timeFrame: 6 months
Other outcomes:
Locations:
city: BRON Cedex
country: France
facility: CH Le Vinatier
state: Rhône-Alpes
Study officials:
affiliation: Centre Hospitalier le Vinatier
name: POISSON Alice, PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05345210: Vonoprazan Hp Dual or Triple Eradication Regimes
Official title: Efficacy and Safety of Helicobacter Pylori Eradication Dual or Triple Regimes Using Vonoprazan as the Antacid
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Helicobacter Pylori
Lead sponsor: Xijing Hospital of Digestive Diseases
Sponsor class: OTHER
First posted: 2022-04-25
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of dual or triple regimes for Helicobacter Pylori eradication using Vonoprazan as the antiacid agent.


Eligibility criteria: Inclusion Criteria:

* Age 18 to 70 years old, both gender is eligiable;
* Patients with definite Helicobacter Pylori infection (13C/14C urea breath test, rapid urease test and fecal Helicobacter Pylori antigen test positive) ;
* Voluntary to accept Helicobacter Pylori eradication treatment;
* Females of childbearing age are required to use medically acceptable contraceptive methods during the trial and within 30 days after the trial.

Exclusion Criteria:

* Patients with contraindications to the study drug or allergic to the study drug;
* Severe organ damage and complications (such as liver cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases;
* Continuous use of anti-ulcer drugs, antibiotics or bismuth complexes (at least 2 weeks before the examination for Helicobacter Pylori infection);
* Pregnant and lactating women;
* Have received upper gastrointestinal surgery;
* Symptoms of dysphagia;
* Evidence of bleeding or iron deficiency anemia;
* have a history of malignant tumor;
* History of drug or alcohol abuse within the past 1 year;
* Systemic application of glucocorticoids, non-steroidal anti-inflammatory drugs, anticoagulants, and platelet aggregation inhibitors (except aspirin ≤100 mg/d);
* Persons with mental disorders;
* Received other clinical trials within the past 3 months;
* Refused to sign the informed consent.

Primary outcomes:
measure: Helicobacter Pylori eradication rate
timeFrame: 28 days after treatment
Secondary outcomes:
measure: symptoms effective rates
timeFrame: 14 days of treatment, and 28 days after treatment
measure: adverse events
timeFrame: 14 days of treatment, and 28 days after treatment
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hosipital of Digestive Disease
state: Shaanxi
Study officials:
affiliation: Xijing Hosipital of Digestive Disease
name: Ying Han
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02686710: Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients
Official title: Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Glycogen Synthase Kinase 3
Lead sponsor: Moscow Regional Research and Clinical Institute (MONIKI)
Sponsor class: OTHER_GOV
First posted: 2016-02-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Assessment of GSK-3beta contents in leukocytes in on-pump cardiosurgical patients receiving either volatile or intravenous anesthesia


Eligibility criteria: Inclusion Criteria:

elective on-pump CABG

Exclusion Criteria:

re-operation

Primary outcomes:
measure: Gsk-3beta base line content
timeFrame: base line
measure: Gsk-3beta content after induction
timeFrame: 20 minutes after tracheal intubation
measure: Gsk-3beta content after surgery
timeFrame: immediately after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy
Study officials:
References:
Clinical trial NCT04320810: Developing Metagenomic Approaches to Identify the Causes of Pediatric Infectious Diseases
Official title: Developing Metagenomic Approaches to Identify the Causes of Pediatric Infectious Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Infectious Disease
Keywords: Metagenome next generation sequencing
Pediatric
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2020-03-25
Enrollment: 1000
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study mainly focus on the pediatric patients who is suspected of infectious disease.

Brief summary: Infectious diseases remain leading causes of mortality and morbidity in children. Rapid and accurate diagnosis of infectious diseases in children is important for developing an effective treatment and management strategy. However, the current diagnosis of infectious agents mainly depends on culture and molecular testing. Both of the methods either has long turnaround times or narrow detection range. Metagenome next generation sequencing (mNGS) has been applied to the diagnosis of central nervous system infection, lower respiratory tract infection and sepsis, which showed high positive rate, short turnaround time. However, there is currently no assessment of the diagnostic efficacy of mNGS in children infectious diseases. This study used the DNA extraction and library construction technology developed for children's low volume clinical samples to assess the sensitivity and specificity of mNGS in the diagnosis of infectious diseases, and the treatment outcome based on mNGS test results.


Eligibility criteria: Inclusion Criteria:

* Patients are highly suspected of sepsis；
* Patients are highly suspected of respiratory infections；
* Patients are highly suspected of central nervous system infection；
* Patients are highly suspected of fever of unknown origin

Exclusion Criteria:

* Congenital malformations；
* Patients requiring surgical intervention;
* Patients with skin barrier dysfunction

Primary outcomes:
measure: The sensitivity of metagenome next generation sequencing in the diagnosis of pediatric infectious disease
timeFrame: From the date of first samples enrolled until the last samples detected, up to 3 years
measure: The specificity of metagenome next generation sequencing in the diagnosis of pediatric infectious disease
timeFrame: From the date of first samples enrolled until the last samples detected, up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children Hospital of Fudan University
state: Shanghai
Study officials:
affiliation: Children's Hospital of Fudan University
name: Wenhao Zhou, Doctor
role: STUDY_CHAIR
References:
Clinical trial NCT01599910: Scribes in the Emergency Department
Official title: The Effect of Scribes in the Emergency Department
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Scribes in the Emergency Department
Keywords: Scribes
Physician Productivity
Electronic Documentation
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
First posted: 2012-05-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult emergency department patients

Brief summary: This study will evaluate the effect of scribes on an academic emergency department.

Detailed description: This study will be a prospective before-after study with washout period of various performance measures before and after the implementation of ED scribes. We will also collect survey data to measure physician satisfaction and patient perception of scribes.

Eligibility criteria: Inclusion Criteria:

* All consecutive patients during the study period
* age \> 18 y/o

Exclusion Criteria:

* Patients seen during the washout period

Primary outcomes:
measure: Time to attending chart completion
timeFrame: 6 months
Secondary outcomes:
measure: Physician productivity
timeFrame: 6 months
measure: Physician Reimbursement
timeFrame: 6 months
measure: Quality of Documentation
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
affiliation: Beth Israel Deaconess Medical Center
name: Steven Horng, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03236610: Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir
Official title: Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir Combination Therapy-Multicenter Randomized Open-label Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
Lead sponsor: Uijeongbu St. Mary Hospital
Sponsor class: OTHER
First posted: 2017-08-02
Enrollment: 112
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Little is known about efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic ehpatitis B patients who achieved a complete virological response to entecavir and tenofovir. This study aimed to investigate the efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic hepatitis B patients with undetectable heaptitis B virus DNA while on tenofovir plus entecavir combination therapy.


Eligibility criteria: Inclusion Criteria:

* HBsAg (+) for \> 6 months age \>19 years antiviral resistance to LAM(rtL180M and/or M204V/I) \& ADV (rtA181V/T and/or rtN236T) or ETV (rtT184A/C/F/G/I/L/S, rtS202G, or rtM250L/V, in addition to rtM204V/I) HBV DNA levels \<20 IU/ml on two consecutive tests of 3-month interval currently receiving TDF+ETV for more than 12 months

Exclusion Criteria:

* Cr ≥1.5 mg/dL Evidence of decompensated liver disease Malignant neoplasm Coinfection with HIV, HCV

Primary outcomes:
measure: SVR at week 48
timeFrame: 48 week
Secondary outcomes:
Other outcomes:
Locations:
city: Uijongbu
country: Korea, Republic of
facility: Uijeongbu St. Mary Hospital
Study officials:
References:
Clinical trial NCT04699110: Adrenaline for the Treatment of No-Reflow in Normotensive Patients
Official title: Efficacy of Intracoronary Adrenaline and Its Comparison With Intracoronary Adenosine in the Treatment of No-Reflow in Normotensive Patients With Acute Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Coronary Syndrome
No-Reflow Phenomenon
Normotensive
Lead sponsor: National Institute of Cardiovascular Diseases, Pakistan
Sponsor class: OTHER
First posted: 2021-01-07
Enrollment: 201
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial coronary vessels in the setting of percutaneous coronary intervention (PCI). It has been demonstrated that either impaired flow or the absence of flow is associated with an increased rate of mortality. Among available treatment options, intracoronary adenosine is widely used in clinical practice, moreover, adrenaline is a safe alternative for the cases where use of adenosine is limited due to presence of hypotension or bradycardia. Nonetheless, evidence from retrospective and observational studies suggest that intracoronary adrenaline is well tolerated and may exert encouraging effects in prompt recovery of flow in these patients. However, very limited data are available on efficacy of intracoronary (IC) adrenaline in normotensive patients. Therefore, this study is planned to study the hypothesis that; intracoronary adrenaline is safe and has significantly higher efficacy as compared to adenosine for the treatment of no-reflow in normotensive patients with acute coronary syndrome.


Eligibility criteria: Inclusion Criteria:

* All patients with acute coronary syndrome who developed No-reflow during PCI.
* Patients with systolic blood pressure of \> 100 mmHg.

Exclusion Criteria:

* Hypotensive patients
* Patients with Valvular or congenital heart disease.
* Patients with Atypical chest pain
* Patients with Cardiomyopathy
* Patients with Pericarditis
* Patients with Myocarditis
* Patients refused to give consent

Primary outcomes:
measure: Improvement in Thrombolysis in Myocardial Infarction (TIMI) flow grade
timeFrame: Immediately after administration of drug
measure: Reduction in TIMI frame count
timeFrame: Immediately after administration of drug
Secondary outcomes:
measure: The major adverse cardiovascular events
timeFrame: During hospital stay and at 30-day follow-up
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: National Institute of Cardiovascular Diseases
state: Sindh
Study officials:
References:
citation: Khan KA, Qamar N, Saghir T, Sial JA, Kumar D, Kumar R, Qayyum D, Yasin U, Jalbani J, Karim M. Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial). Circ Cardiovasc Interv. 2022 Feb;15(2):e011408. doi: 10.1161/CIRCINTERVENTIONS.121.011408. Epub 2022 Jan 10.